Thackray Helen M. has filed 12 insider transactions across 1 company since April 2023.
Most recent transaction: a tax payment of 7525 shares of BIOCRYST PHARMACEUTICALS INC ($BCRX) on March 31, 2025.
Activity breakdown: 1 open-market purchase and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2025 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 7525 | $7.50 | 377,318.0000 | 206,696,000 | 1.96% | 0.00% |
| Dec. 19, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | A | Common Stock | 125950 | $0.00 | 390,939.0000 | 206,905,000 | 47.53% | 0.06% |
| Dec. 19, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 6096 | $7.39 | 384,843.0000 | 206,905,000 | 1.56% | 0.00% |
| Dec. 19, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | A | Emp. Stock Option (Right to Buy) | 260950 | $0.00 | 260,950.0000 | 206,905,000 | 9999.99% | 0.13% |
| Dec. 14, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 7150 | $7.53 | 264,989.0000 | 206,905,000 | 2.63% | 0.00% |
| May 14, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | P | Common Stock | 30000 | $5.86 | 272,139.0000 | 192,198,000 | 12.39% | 0.02% |
| March 31, 2024 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 7525 | $5.08 | 242,139.0000 | 192,198,000 | 3.01% | 0.00% |
| Dec. 19, 2023 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 5580 | $6.05 | 249,664.0000 | 185,908,000 | 2.19% | 0.00% |
| Dec. 14, 2023 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | A | Common Stock | 51000 | $0.00 | 258,275.0000 | 185,908,000 | 24.60% | 0.03% |
| Dec. 14, 2023 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | F | Common Stock | 3031 | $6.43 | 255,244.0000 | 185,908,000 | 1.17% | 0.00% |
| Dec. 14, 2023 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | A | Emp. Stock Option (Right to Buy) | 238000 | $0.00 | 238,000.0000 | 185,908,000 | 9999.99% | 0.13% |
| April 3, 2023 | BIOCRYST PHARMACEUTICALS INC | $BCRX | Thackray Helen M. | Chief R&D Officer | S | Common Stock | 7000 | $8.29 | 207,275.0000 | 185,908,000 | 3.27% | 0.00% |